30th week of 2015 patent applcation highlights part 21 |
Patent application number | Title | Published |
20150203548 | Single-Domain Antibodies with Improved Thermal Stability Under Cytoplasmic Expression - Methods of producing a single-domain antibody (sdAb) include causing a bacteria to express the sdAb into cytoplasm of the bacteria, wherein the sdAb is expressed as a fusion protein with the acid tail of α-synuclein; and then purifying the sdAb, wherein the fusion protein is expressed free of a periplasmic location tag. Such antibodies have the unexpected ability to refold after thermal denaturation. | 2015-07-23 |
20150203549 | COMPOSITIONS AND METHODS FOR BROWN FAT INDUCTION AND ACTIVITY USING FNDC5 - The invention provides compositions and methods for brown fat induction and activity through modulation of Fndc5 activity and/or expression. Also provided are methods for preventing or treating metabolic disorders in a subject through modulation of Fndc5 activity and/or expression. Further provided are methods for identifying compounds that are capable of modulating Fndc5 activity and/or expression. | 2015-07-23 |
20150203550 | IgE PEPTIDE VACCINE - It is intended to provide an IgE peptide vaccine that can be used in the prevention or treatment of allergic diseases in animals other than mice, such as humans or dogs. The present invention provides a peptide consisting of (i) the amino acid sequence represented by SEQ ID NO: 28, or (ii) an amino acid sequence consisting of at least 10 consecutive amino acids in the amino acid sequence represented by SEQ ID NO: 28, wherein the peptide, when administered to an animal, is capable of specifically binding to a CH3 region in an IgE antibody of the animal and thereby blocking the binding of the IgE antibody to an IgE receptor. | 2015-07-23 |
20150203551 | HMGB1 VARIANTS AND USES THEREOF - The present invention relates to HMGB1 variants that maintain HMGB1 wild type chemoattractant function while displaying abolished cytokine and/or chemokine stimulating properties. Such molecules are useful in therapy. | 2015-07-23 |
20150203552 | METHOD FOR THE PREPARATION OF A SERUM PROTEIN CONCENTRATE - The present invention relates to a method for the preparation of a concentrate of serum proteins with reduced lactose content from a sample of lactoserum, wherein said concentrate is characterized in that it comprises a concentration of 0.5 grams of lactose per kilogram of protein, the concentrate obtainable from said process and food products containing said concentrate. | 2015-07-23 |
20150203553 | AAV MEDIATED AQUAPORIN GENE TRANSFER TO TREAT SJOGREN'S SYNDROME - The invention relates to a gene transfer-based method to protect a subject from Sjogren's syndrome. The method comprises administering to the subject an AAV virion comprising an AAV vector that encodes aquaporin-1 (AQP-1) protein. Also provided are AQP-1 proteins and nucleic acid molecules that encode such proteins. Also dr GFP provided are AAV vectors and AAV virions that encode an AQP-1 protein. | 2015-07-23 |
20150203554 | METHODS AND COMPOSITIONS RELATED TO IMPROVING PROPERTIES OF PHARMACOLOGICAL AGENTS TARGETING NERVOUS SYSTEM - Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system. | 2015-07-23 |
20150203555 | ALPHA/BETA-PEPTIDE MIMICS OF Z-DOMAIN PEPTIDES - Described are α/β-peptide mimics of Z-domain scaffold peptides, methods of making them, and methods of using them. The α/β-peptide mimics include β-amino acid residues and, optionally, disulfide bonds to stabilize the conformation of the mimics. The compounds may be truncated as compared to conventional Z-domain scaffold peptides and are resistant to proteolytic degradation due to the presence of β-amino acid residues. The mimics can be made so as to bind selectively to a desired target. | 2015-07-23 |
20150203556 | COMPOSITIONS AND METHODS FOR MODULATION OF IL-20 FAMILY CYTOKINE ACTIVITY - Provided herein are compositions comprising one or more agents that inhibit or reduce the activity of IL-20. Optionally, the agents further inhibit or reduce the activity of IL-24. Kits and method of treating or preventing an inflammatory or autoimmune disease using the compositions are also provided. In addition, provided are methods of screening for agents that selectively bind the IL20R1/IL-20R2 receptor complex or that selectively bind the IL-22R1/IL-20R2 receptor complex. The methods include contacting an agent to be screened with the receptor and determining whether the agent selectively binds to the receptor. | 2015-07-23 |
20150203557 | MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLS - A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described. | 2015-07-23 |
20150203558 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME - A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed. | 2015-07-23 |
20150203559 | PROPROTEINS AND METHODS OF USE THEREOF - The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins. | 2015-07-23 |
20150203560 | ENGINEERED ANTIBODY-INTERFERON FUSION MOLECULES FOR TREATMENT OF AUTOIMMUNE DISEASES - The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (IFN) molecule attached to an antibody (Ab) which targets an antigen which is differentially expressed or up-regulated on activated T cells as compared to resting T cells, wherein the fusion molecule when contacted to an activated T cell results in induced apoptosis and programmed cell death or impairment of functions of said activated T cell. | 2015-07-23 |
20150203561 | BETA THYMOSIN FRAGMENTS - Peptide fragments having amino acid sequences corresponding to portions of a thymosin beta 4, a thymosin beta 10 and/or a thymosin beta 15 amino acid sequence are provided, as well as methods of treatment utilizing same. | 2015-07-23 |
20150203562 | COMPOUNDS AND METHODS FOR MODULATING PHARMACOKINETICS - Methods and compositions are described for management of the pharmacokinetic properties of active agents, e.g., therapeutic moieties, by conjugating, fusing, or non-direct linkage of the active agent to one or more wild-type or modified heparin-binding peptides (HB). Compounds may be administered to tissues including skin. Contemplated uses include treatment of disease, allergen immunotherapy, and immunization. Other aspects relate to compositions, methods and kits comprising heparin-binding peptides (HB) fused or conjugated to the therapeutic agents. | 2015-07-23 |
20150203563 | COMPOSITIONS AND METHODS FOR TREATING HYPERTENSION - The technology described herein is directed to agents that reduce the level of oxidant-modified ET-B Cys405, Cys403, or Cys402 and the identification and use of such agents for, e.g. to treat hypertension. | 2015-07-23 |
20150203564 | B7-H5, A Costimulatory Polypeptide - B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein. | 2015-07-23 |
20150203565 | B-CELL ACTIVATING FACTOR FOR INCREASING MUCOSAL IMMUNITY OF INFANTS AS WELL AS SUCKLINGS AND A PREPARATION CONTAINING THIS FACTOR - B-cell activating factor increases mucosal immunity of infants or sucklings and is provided in a preparation for peroral administration, containing B-cell activating factor, intended for stimulation of mucosal immunity of infants or sucklings. | 2015-07-23 |
20150203566 | FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES - Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent. | 2015-07-23 |
20150203567 | FVIII PEPTIDES FOR IMMUNE TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS - The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4 | 2015-07-23 |
20150203568 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2015-07-23 |
20150203569 | METHOD OF MAKING COLLAGEN POWDER FROM MARINE CARTILAGE AND SKIN - A method of making hydrolyzed marine Type II collagen includes the mixing of marine cartilage, water, an enzyme and a protease enzyme for an extended period of time. Once mixed, the mixture is heated for a period of time at 150° F. Once heated, the enzymes are deactivated, the bone sediment separated, and the fat removed. Next, maltodextrin is added to the mixture and finally the mixture is spray dried to form a collagen powder. | 2015-07-23 |
20150203570 | PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO SPHINGOSINE-1-PHOSPHATE - The present invention relates to use of anti-S1P agents, for example, humanized monoclonal antibodies, for prevention and/or treatment of pain, including neuropathic pain, hyperalgesia, allodynia, and chemotherapy-induced pain. | 2015-07-23 |
20150203571 | ANTIBODIES TO ION CHANNELS - An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies. | 2015-07-23 |
20150203572 | Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted Immunoglobulin Reactive to a Second Antigen - Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen. | 2015-07-23 |
20150203573 | MONOCLONAL ANTIBODY AGAINST HUMAN MIDKINE - A monoclonal antibody, which recognizes at least two amino acids among amino acids located at position 69, position 79, position 81 and position 102 of human midkine, has been found to have excellent reactivity with and excellent neutralizing activity against human midkine. Moreover, the activity of suppressing the proliferation of tumor has been observed in the antibody having excellent neutralizing activity. The use of the antibody of the present invention makes it possible to treat cancer effectively and to detect or purify midkine efficiently. | 2015-07-23 |
20150203574 | ANTIBODIES TO IL-6 AND THEIR USES - Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions. | 2015-07-23 |
20150203575 | PILR ALPHA INTERACTIONS AND METHODS OF MODIFYING SAME - Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders. | 2015-07-23 |
20150203576 | Variants of IgG Fc with Limited Amine Groups - Lysine-depleted variants of fragment crystallizable (Fc) regions of immunoglobulins are disclosed. Also disclosed are fusion proteins comprised of N-terminal targeting or active peptide domains fused with such lysine-depleted variant IgG-Fc domains. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed. | 2015-07-23 |
20150203577 | MOUSE FcgammaRII-SPECIFIC Fc ANTIBODY - The present inventors have successfully found a large number of Fc variants with remarkably increased binding activity against and/or binding selectivity for mouse FcγRII by introducing amino acid alteration(s) to the Fc region. | 2015-07-23 |
20150203578 | ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF - The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies. | 2015-07-23 |
20150203579 | Human Antibodies to PD-1 - The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder. | 2015-07-23 |
20150203580 | Human Antibodies to PD-L1 - The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection. | 2015-07-23 |
20150203581 | NOVEL ANTI- ALPHA5 BETA1 ANTIBODIES AND USES THEREOF - The present invention provides new anti-α5β1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies. | 2015-07-23 |
20150203582 | METHOD OF GENERATING ANTIBODIES - The present invention discloses a reliable and efficient method of generating an antibody which can discriminate between the membrane bound form of an antigen and the soluble form of the same antigen. Said method comprises the steps of: (i) immunizing an animal with a first antigen which comprises either the membrane bound form or the soluble form of the antigen; (ii) administering to the animal an agent which selectively kills rapidly dividing cells; (iii) when the first antigen of step (i) comprises the soluble form, immunizing the animal with a second antigen which comprises the membrane bound form of the antigen, or when the first antigen of step (i) comprises the membrane bound form, immunizing the animal with a second antigen which comprises the soluble form of the antigen; and (iv) screening for an antibody which can bind to the second antigen but which does not bind to the first antigen. | 2015-07-23 |
20150203583 | DAC HYP COMPOSITIONS AND METHODS - The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof. | 2015-07-23 |
20150203584 | ANTI IL-36R ANTIBODIES - The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same. | 2015-07-23 |
20150203585 | Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System - The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist. | 2015-07-23 |
20150203586 | MACROMOLECULAR COMPOSITIONS THAT CROSS THE BLOOD-BRAIN BARRIER AND METHODS OF USE THEREOF - The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease. | 2015-07-23 |
20150203587 | ANTI-CD38 ANTIBODIES - Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies. | 2015-07-23 |
20150203588 | Cancer Biomarkers and Methods of Use Thereof - Methods and compositions for treating cancer, particularly breast cancer, are disclosed. | 2015-07-23 |
20150203589 | FUSION PROTEINS AND METHODS THEREOF - The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers. | 2015-07-23 |
20150203590 | LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE - The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject. | 2015-07-23 |
20150203591 | MUTIVALENT ANTIGEN-BINDING PROTEINS - Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Proteins comprising two or three or four or more different heavy chain variable domains that lack an immunoglobulin variable domain are provided. Proteins comprising two or three or four or more different heavy chain variable domains that associate with the same immunoglobulin light chain variable domain are also provided. | 2015-07-23 |
20150203592 | COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS - The present invention relates to the treatment of osteoarthritis in a human subject using anti-IL-1α and anti-IL-1β DVD-Ig proteins. In various embodiments, the osteoarthritis includes knee osteoarthritis or hand osteoarthritis. | 2015-07-23 |
20150203593 | SOLID SUPPORT WITH A GRAFTED CHAIN - Articles that contain a solid support with a grafted chain extending from the solid support, methods of making these articles, and various uses of the articles are described. More specifically, the grafted chain has a functional group that can react with or interact with target compound. Alternatively, the functional group on the grafted chain can react with a modifying agent to provide another group that can react with or interact with the target compound. The grafted chains are attached to the solid support through a ring-opened azlactone group. The articles can be used to purify the target compound or to separate the target compound from other molecules in a sample. | 2015-07-23 |
20150203594 | Topographically Functionalized NFC Film as an Immunoassay Platform for Rapid Diagnostics - The present invention concerns a method for functionalization, via topographical modification, of the surfaces of nanofibrillated (NFC) cellulose films into non-porous, water-resistant platforms, usable in diagnostic applications. The method includes a carboxylation of the NFC-film via TEMPO-mediated oxidation, and optionally an activation via EDS/NHS chemistry and, finally, the reactivity of the film can be tested using anti-human IgG. The invention also concerns the thus prepared functionalized NFC films, as well as the use thereof as platforms for diagnostical assays. | 2015-07-23 |
20150203595 | PROCESS FOR PREPARING AN ESTER OF A CELLULOSE ETHER IN THE PRESENCE OF AN ALKALI METAL CARBOXYLATE - Two or more esters of a cellulose ether, each having the same ether and ester substituents but different weight average molecular weights are prepared in a process which comprises the steps of esterifying a cellulose ether with (i) an aliphatic monocarboxylic acid anhydride or (ii) a dicarboxylic acid anhydride or (iii) a combination of an aliphatic monocarboxylic acid anhydride and a dicarboxylic acid anhydride in the presence of an alkali metal carboxylate in two or more separate reactions, wherein in each reaction a different molar ratio [alkali metal carboxylate/anhydroglucose units of cellulose ether] is used to produce esters of the cellulose ether of different weight average molecular weights. | 2015-07-23 |
20150203596 | METHOD FOR PREPARING ACETYLATED CELLULOSE ETHERS HAVING IMPROVED ANTI-FOULING PROPERTIES, AND ACETYLATED CELLULOSE ETHERS PREPARED BY SAME - The present invention relates to a method for preparing acetylated cellulose ethers having improved anti-fouling properties and to acetylated cellulose ethers prepared by same. The method for preparing acetylated cellulose ethers having improved anti-fouling properties comprises the steps of: cross-linking cellulose ethers; and acetylating the cross-linked cellulose ethers. The acetylated cellulose ethers prepared by the method may activate the hydroxyl group which is made into blocks by the agglomeration between polymers performed by the materials for cross-linking the cellulose ethers, and may introduce thereto an additional hydrophilic group so as to increase hydrophilic properties, and thus may improve anti-fouling properties when applied to water-treatment membranes. | 2015-07-23 |
20150203597 | PARTIALLY CROSS-LINKED ESTERIFIED CELLULOSE ETHERS - A partially cross-linked esterified cellulose ether having A) groups of the formula —C(O)—R—COOA or a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, and B) having a molecular weight distribution such that [Wf(>100 k)−Wf(>100 k)XL]/Wf(>100 k)XL is at least 0.20, wherein Wf(>100 k) is the total weight fraction of the esterified cellulose ether that exceeds 100,000 g/mol, and Wf(>100 k)XL is the weight fraction that exceeds 100,000 g/mol of the methylated esterified cellulose ether is useful as enteric polymer for pharmaceutical dosage forms. | 2015-07-23 |
20150203598 | ALTERNAN POLYSACCHARIDE THAT IS FUNCTIONALIZED WITH NITROGEN GROUPS THAT CAN BE PROTONATED, OR WITH PERMANENTLY POSITIVELY CHARGED NITROGEN GROUPS - Functionalized alternan polysaccharide, comprising nitrogen groups or permanently positively charged nitrogen groups that can be protonated as functional groups and can be described by the following formula, for instance: (I) wherein R | 2015-07-23 |
20150203599 | POLYSACCHARIDE SYNTHASES (X) - The present disclosure relates generally to polysaccharide synthases. The present disclosure reveals that a subset of the CesA gene family encode XynS xylan synthases. As a result of the identification of XynS nucleic acids, and corresponding amino acid sequences that encode XynS xylan synthases, the present invention provides, inter alia, methods and compositions for modulating the level and/or activity of xylan synthase in a cell and/or modulating the level of xylan produced by a cell. | 2015-07-23 |
20150203600 | PROCESS FOR THE PRODUCTION OF WATER AND SOLVENT-FREE POLYMERS - The present invention relates to water and solvent-free polymers, in particular water and solvent-free synthetic rubber products like non-halogenated and halogenated butyl rubber products as well as a process for the production thereof. The invention further relates to a device suitable to accomplish said process. | 2015-07-23 |
20150203601 | Monomer/Diluent Recovery - The disclosure includes a polymerization process and an olefin polymerization system. A polymerization product is produced, a vapor phase is recovered from the polymerization product, the vapor phase is fractionated in a first column to yield a fraction stream, and the fraction stream is fractionated in a second column. A first stream of the second column, which comprises a diluent, can be recycled to a first polymerization reactor. A second stream of the second column, which comprises olefin monomer, diluent, and hydrogen, can be recycled to a second polymerization reactor. Comonomer may be recycled from the first column to the first polymerization reactor, the second polymerization reactor, or both. | 2015-07-23 |
20150203602 | METHOD OF MAKING AN OLEFIN POLYMERIZATION CATALYST ACTIVATOR - A method for preparing ammonium tetrakis(pentafluorophenyl)borate salt comprising reacting a secondary amine with an aldehyde to form an iminium ion; hydrogenating the iminium ion by reaction with a reducing agent to form a tertiary amine; reacting the tertiary amine with a mineral acid to form an amine salt; and reacting the amine salt with K[B(C | 2015-07-23 |
20150203603 | ACTIVATED CLAY FOR TREATING AROMATIC HYDROCARBONS - An activated clay for treating aromatic hydrocarbons, containing montmorillonite in an amount of not less than 34% by mass, having an SiO | 2015-07-23 |
20150203604 | CATALYST FOR POLYMERIZATION OF OLEFINS AND PROCESS THEREOF - The present invention provides a process for preparation of a solid titanium catalyst component for use as pro-catalyst for a Ziegler-Natta catalyst system. The solid titanium catalyst component comprises a combination of 15 to 20 wt % of a magnesium moiety, 1.0 to 6.0 wt % of a titanium moiety and 5.0 to 20 wt % of an internal donor, said solid titanium catalyst component has an average particle size in the range of 1 to 100 μm, characterized by a three point particle size distribution of D10 in the range of 1 to 10 μm; D50 in the range of to 25 μm and D90 in the range of 15 to 50 μm. The present invention also provides a 15 Ziegler-Natta catalyst system comprising the solid titanium catalyst component and the method of polymerizing and/or copolymerizing olefins by using the Ziegler-Natta catalyst system. | 2015-07-23 |
20150203605 | CATALYST FOR OLEFIN POLYMERIZATION AND A METHOD FOR THE PREPARATION THEREOF - In accordance with the present disclosure, a method of preparing a solid support for a transition metal catalyst is disclosed. The solid support may have a unique morphology that may be derived from contacting the magnesium compound and an electron donor in the presence of a fluorinated organic compound to form the solid support. The solid support may be used to form an enhanced catalyst. The enhanced catalyst may be used, in combination with an organoaluminum compound, as a Ziegler-Natta (ZN) catalyst. The ZN catalyst including the enhanced catalyst may be used to form a UHMWPE. | 2015-07-23 |
20150203606 | Apparatus and Process for Making High-Pressure Polyethylene Polymers and Copolymers - Embodiments of the invention provide an apparatus for the manufacture of polyethylene and polyethylene copolymers. The apparatus includes a primary compressor in fluid communication with a two-stage secondary compressor, the secondary compressor in fluid communication with a heated conduit in fluid communication with a tubular reactor, the tubular reactor including one or more reaction zones having a heating/cooling jacket, said reactor tube including an inner material and an outer material, said outer material being substantially inert in the presence of water under operating conditions, the tubular reactor in fluid communication with a product separator, and at least one conduit for the transfer of recycled ethylene from the product separator to the secondary compressor. Processes for manufacturing polyethylene and polyethylene copolymers using such an apparatus are also described. | 2015-07-23 |
20150203607 | CROSS-LINKED POLYETHYLENE FIBRE, ITS USE AND PROCESS FOR ITS MANUFACTURE - The present invention relates to a polymer fiber, in particular a polyethylene polymer fiber obtainable by melt-spinning of a polyethylene polymer, the use of the fiber and a process for the manufacture of the fiber. Further, the present invention relates to a heat sealable filter paper comprising said polymer fiber. | 2015-07-23 |
20150203608 | PIGMENT DISPERSING AGENT, PIGMENT DISPERSION SOLUTION, COLOR PHOTORESIST AND MANUFACTURE AND USE THEREOF - A pigment dispersing agent, a pigment dispersion solution, a color photoresist, and a process for manufacturing the same, and use in the color film substrate and display device. The pigment dispersing agent is an amino-β-cyclodextrin modified polymethacrylate, the amino-β-cyclodextrin modified polymethacrylate being used to disperse a powdered pigment having an aromatic group, wherein the degree of modification by amino-β-cyclodextrin is 5.36%-35.40%. Because β-cyclodextrin moiety is a group having affinity for pigments, it can bind to the aromatic group in the pigment molecular structure, thereby capable of dispersing the powdered pigment having an aromatic group. The pigment dispersion solution prepared from the pigment dispersing agent has small particle size, narrow particle size distribution range, and high storage stability, thereby improving the yield of the display product. | 2015-07-23 |
20150203609 | PHOTOPOLYMERISATION PROCESSES AND NOVEL COMPOUNDS THEREFOR - A process for photopolymerising a photopolymerisable compound having at least one ethylenically unsaturated double bond, comprises contacting said photopolymerisable compound with a photoactive oxide and irradiating it, wherein the photoactive oxide includes one or more moieties together with a moiety wherein there are at least 2 atoms between moiety I and moiety II in the additive and where X represents an oxygen or sulphur atom. Novel compounds which exhibit beneficial effects on cure in the presence of oxygen, which may be especially advantageous when LEDs are used, are also described. | 2015-07-23 |
20150203610 | COPOLYMER FOR IMPROVING METHACRYLIC RESIN HEAT RESISTANCE - A copolymer for improving heat resistance of a methacrylic resin which can achieve preservation of excellent transparency of the methacrylic resin and improvement in heat resistance, and can provide a molded product having excellent appearance, by adding the copolymer to the methacrylic resin, is provided. According to the present invention, a copolymer for improving heat resistance of a methacrylic resin, including: 45 to 85 mass % of an aromatic vinyl monomer unit; 5 to 45 mass % of a (meth)acrylic acid ester monomer unit; and 10 to 20 mass % of an unsaturated dicarboxylic acid anhydride monomer unit; wherein the copolymer has a total light transmittance of 88% or more, the total light transmittance being measured in accordance with ASTM D1003 for a sample with 2 mm-thickness, is provided. | 2015-07-23 |
20150203611 | PROCESS FOR THE PREPARATION OF DIENE POLYMERS OR OF RANDOM VINYL ARENE-DIENE COPOLYMERS - Process for the preparation of diene polymers or random vinyl arene-diene copolymers which comprises (co) polymerizing, anionically, in the presence of at least one hydrocarbon solvent, at least one conjugated diene monomer and optionally at least one vinyl arene, in the presence of at least one lithium-based initiator, at least one aprotic polar compound, and at least one compound containing one or more functional groups of the acetylenic type. Said process allows diene polymers or random vinyl arene-diene copolymers to be obtained, which can be advantageously used in the production of tyres, in particular in the production of tyre treads. The diene polymers or the random vinyl arene-diene copolymers obtained through said process can also be used for the modification of plastic materials [for example, for obtaining high impact polystyrene (HIPS)]. | 2015-07-23 |
20150203612 | SURFACE MODIFICATION METHOD AND SURFACE-MODIFIED ELASTIC BODY - The present invention aims to provide methods for surface-modifying a rubber vulcanizate or a thermoplastic elastomer, which can cost-effectively impart a variety of functions, such as sliding properties or biocompatibility, according to the application. The present invention relates to a method for surface-modifying an object of a rubber vulcanizate or a thermoplastic elastomer, the method including: step 1 of forming polymerization initiation points A on the surface of the object; and step 2 of radically polymerizing a non-functional monomer, starting from the polymerization initiation points A, to grow non-functional polymer chains, and further radically polymerizing a fluorine-containing functional monomer to grow fluorine-containing functional polymer chains. | 2015-07-23 |
20150203613 | SULFUR-MODIFIED CHLOROPRENE RUBBER COMPOSITION AND MOLDED BODY - An object of the invention is to provide a sulfur-modified chloroprene rubber composition improved in heat resistance. A sulfur-modified chloroprene rubber composition, comprising a sulfur-modified chloroprene rubber containing sulfur chemically bound thereto and sulfur not chemically bound to the sulfur-modified chloroprene rubber, wherein: the ratio of the amount of sulfur chemically bound to the sulfur-modified chloroprene rubber to the total amount of sulfur in the sulfur-modified chloroprene rubber composition (amount of chemically bound sulfur [mass %]/total amount of sulfur [mass %]) is 0.1 to 0.45; and the sulfur-modified chloroprene rubber has, at the molecular terminal, at least one structure represented by the following General Formula (1) or (2): —S—C(═S)—O—R | 2015-07-23 |
20150203614 | Long Chain Branched Polymers and Methods of Making Same - A polymer having a long chain branching content peaking at greater than about 20 long chain branches per million carbon atoms, and a polydispersity index of greater than about 10 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution. A polymer having a long chain branching content peaking at greater than about 8 long chain branches per million carbon atoms, a polydispersity index of greater than about 20 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution. A polymer having a long chain branching content peaking at greater than about 1 long chain branches per chain, and a polydispersity index of greater than about 10 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution. | 2015-07-23 |
20150203615 | ALKALI METAL-ZINC IONOMER COMPOSITIONS - Disclosed are ionomer compositions comprising ionomers neutralized with a combination of alkali metal cations and zinc cations, methods to form aqueous dispersions comprising the ionomers and methods to form coatings comprising the ionomers on substrates. | 2015-07-23 |
20150203616 | Ethylene Copolymers with a Novel Composition Distribution and Processes for Making the Same - A Ziegler-Natta catalyzed ethylene copolymer having a novel composition distribution in which comonomers are incorporated into the high molecular weight polymer molecules and distributed evenly among the entire polyethylene chains, and a method for making the same are provided. The resins having a novel composition distribution have controlled molecular weight distribution which is narrower than conventional ZN-ethylene copolymers but broader than single-site catalyzed ethylene copolymers. The resins having a novel composition distribution exhibit a superior tear strength and impact strength. | 2015-07-23 |
20150203617 | Methods for Producing Fluorided-Chlorided Silica-Coated Alumina Activator-Supports and Catalyst Systems Containing the Same - Methods for the preparation of fluorided-chlorided silica-coated alumina activator-supports are disclosed. These activator-supports can be used in catalyst systems for the production of olefin-based polymers, such as polyethylene and polypropylene. | 2015-07-23 |
20150203618 | GAMMA RESISTANT ADHESIVES - Adhesives are disclosed which include a methacrylate copolymer, wherein the methacrylate copolymer includes at least one methacrylate monomer component and at least one acrylic or silicone monomer component, and wherein the adhesive are gamma resistant. The adhesives may include about 45% to about 49% by weight acrylic or silicone monomer component, about 45% to about 49% by weight methacrylate monomer component, and about 2% to about 10% by weight acrylic acid or 2-hydroxyethyl acrylate. The adhesives may further include at least one additive selected from the group consisting of a plasticizer, a tackifier, a cross-linking agent, an antioxidant and combinations thereof. The adhesives may be a pressure-sensitive and low trauma adhesive. Also disclosed are medical devices including the adhesives. | 2015-07-23 |
20150203619 | SURFACE-ACTIVE COMB COPOLYMERS - The invention relates to a copolymer whose overall structure as such and/or an optionally present segment A having at least 10 bivalent structural units in the overall structure contains surface-active bivalent structural units present in the form of long hydrocarbon chains among other forms. The copolymer is effective as a universal surface-active additive, especially also in conjunction with nonpolar media. | 2015-07-23 |
20150203620 | POLYMERS OF ISROPENE FROM RENEWABLE RESOURCES - It has been found that certain cells in culture can convert more than about 0.002 percent of the carbon available in the cell culture medium into isoprene. These cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. The isoprene produced in such a cultured medium can then be recovered and polymerized into synthetic rubbers and other useful polymeric materials. The synthetic isoprene containing polymers of this invention offer the benefit of being verifiable as to being derived from non-petrochemical based resources. They can also be analytically distinguished from rubbers that come from natural sources. The present invention more specifically discloses a polyisoprene polymer which is comprised of repeat units that are derived from isoprene monomer, wherein the polyisoprene polymer has δ | 2015-07-23 |
20150203621 | FOAM PRODUCED FROM POLYPROPYLENE WITH LOW GEL CONTENT - Process for providing a polypropylene composition comprising a branched polypropylene in which a polypropylene with a melt flow rate MFR | 2015-07-23 |
20150203622 | Copolymers Having Polyisobutylene And Biodegradable Polymer Segments - The present invention pertains to copolymers having one or more polyisobutylene segments and one or more biodegradable polymer segments, to methods of making such copolymers, to medical articles that contain such copolymers, and to methods of making such medical articles. According to certain aspects of the invention, copolymers are provided, which comprise a plurality of polyisobutylene segments and a plurality of biodegradable polymer segments. According to certain aspects of the invention, copolymers are provided, which comprise urethane linkages, urea linkages, amide linkages, ester linkages, anhydride linkages, carbonate linkages, linkages commonly described as “click” chemistry linkages, and combinations of two or more types of such linkages. | 2015-07-23 |
20150203623 | BINDER WITH CYCLIC CARBONATE STRUCTURES - The invention relates to a method for producing polyurethanes containing cyclic carbonate structures by reacting at least A) a composition containing a) one or more compounds of the general formula (I), said compounds containing isocyanate groups and cyclic carbonate structures, and b) <=1 wt. %, based on the total mass of the composition A), of one or more monomer diisocyanates with aliphatically, cycloaliphatically, araliphatically, and/or aromatically bound isocyanate groups of the general formula (II), wherein R represents hydrogen or a saturated or unsaturated, linear or branched, aliphatic group with 1 to 7 carbon atoms, X represents a linear or branched organic group which comprises 1 to 36 carbon atoms and which can contain optionally ether, ester, and/or carbonate groups, n represents 0 or 1, and Y represents a linear or branched, aliphatic or cycloaliphatic group with 4 to 18 carbon atoms or an optionally substituted aromatic or aliphatic group with 6 to 18 carbon atoms, with B) an at least difunctional polyol with a number-average molecular weight Mn of 62 to 22000 g/mol, preferably 90 to 12000 g/mol, while maintaining an equivalent ratio of isocyanate groups to hydroxyl groups of 0.3:1 to 1.2:1. Furthermore, the invention relates to products which can be obtained using the method according to the invention. The invention additionally relates to the use of the products which can be obtained using the method according to the invention as a starting component in the production of crosslinkable binders, such as paints and raw materials for sealants or adhesives. | 2015-07-23 |
20150203624 | SECOND GENERATION HYBRID SILANE MODIFIED POLYMERS OF LOW VISCOSITY FOR LOW TOXICITY RTV SEALANTS AND ADHESIVES - The present method relates to the production of alcoxysilane capped polymers, as well as the production of sealants and adhesive using the alcoxysilane capped polymers formed from the present method. The method of production results in final alcoxysilane capped polymers that have a low viscosity and are safer for manufacturers, and end users. | 2015-07-23 |
20150203625 | HARDENERS FOR COLD CURING EPOXY SYSTEMS - A hardener composition comprising: a) a non-isolated adduct of i) a monofunctional epoxy; and ii) a first amine; b) a second amine; c) a modifier; and d) an accelerator, is disclosed. The hardener composition can be combined with an epoxy resin to make a composition useful to prepare primers. | 2015-07-23 |
20150203626 | NOVOLAC-BASED EPOXY COMPOUND, PRODUCTION METHOD FOR SAME, COMPOSITION AND CURED ARTICLE COMPRISING SAME, AND USE FOR SAME - A novolac epoxy compound having an alkoxysilyl group of which composite has low CTE and increase of glass transition temperature, and requiring no coupling agent, a production method thereof, an epoxy composition including the same and a cured article thereof, are provided. A novolac epoxy compound having an alkoxysilyl group of Formulae I-1 to I-4, a production method of the novolac epoxy compound having an alkoxysilyl group by the epoxidation, alkenylation and alkoxysilylation of a novolac epoxy compound, a production method of the novolac epoxy compound having an alkoxysilyl group by the epoxidation and alkoxysilylation of a novolac epoxy compound, an epoxy composition including the novolac epoxy compound having an alkoxysilyl group, and a cured article, are provided. The cured article, i.e., the composite of the epoxy composition has improved chemical bonding efficiency due to alkoxysilyl groups. Low CTE and high glass transition temperature are exhibited | 2015-07-23 |
20150203627 | POLYMER NETWORK MATERIAL COMPRISING A POLY(GLYCIDYL ETHER) STRUCTURE, METHOD OF ITS PRODUCTION AND USE - The present invention is related to novel preparative methods to a novel class of polymer network materials with a highly branched poly(glycidyl ether) (PGE) structure. Said polymer networks are prepared by a simple procedure involving ring-opening polymerisation and the method is applicable to a wide range of glycidyl ether containing monomers. The method comprises the step of copolymerising (A) at least one multi-topic glycidyl ether comprising at least three glycidyl ether groups with (B) at least one glycidyl ether component comprising at least one glycidyl ether group by ring opening polymerisation, wherein the multi-topic glycidyl ether (A) is glycerol glycidyl ether (GGE) having the Formula (I) and the glycidyl ether component (B) is selected from monoglycidyl ethers comprising one glycidyl ether group and diglycidyl ethers comprising two glycidyl ether groups. | 2015-07-23 |
20150203628 | EPOXY RESIN SYSTEM CONTAINING POLYETHYLENE TETRAMINES AND TRIETHYLENE DIAMINE CATALYST FOR RESIN TRANSFER MOLDING PROCESSES - A two-component curable epoxy resin system is disclosed. The resin system includes an epoxy resin component containing at least 80% by weight of a polyglycidyl ether of a polyphenol. The system also includes an hardener mixture containing mainly polyethylene tetraamines. The system include triethylene diamine in specific amounts as a catalyst. The system has beneficial curing characteristics that make it useful for producing fiber-reinforced composites in a resin transfer molding process. | 2015-07-23 |
20150203629 | CURABLE COMPOSITIONS BASED ON EPOXY RESINS WITHOUT BENZYL ALCOHOL - The invention relates to curable compositions comprising at least one epoxy resin and at least one hardener wherein the hardener is a compound of formula (I) or (II) | 2015-07-23 |
20150203630 | Polyesters - Polyesters according to the following formula (I) are described | 2015-07-23 |
20150203631 | POLYAMIC ACID RESIN COMPOSITION, POLYIMIDE FILM USING SAME, AND METHOD FOR PRODUCING SAID POLYIMIDE FILM - An object is to provide a polyamic acid resin composition that can form a varnish with a low viscosity and serves to produce, through curing, coat film with good mechanical characteristics. Another object is to provide a polyamic acid resin composition in which the acid anhydride terminal group is low in reactivity with diamine and which can give a varnish that does not suffer significant precipitation of diamine. These objects can be met by a polyamic acid resin composition that contains: (a) polyamic acid and (b) a compound as represented by chemical formula (1). (In Chemical formula (1), Z is a di- or higher-valent organic group containing 2 or more carbon atoms, V is a structure as represented by chemical formula (2), and k is an integer of 2 or more.) (In In Chemical formula (2), δ represents oxygen or sulfur atom and W represents an electron-withdrawing group, and R | 2015-07-23 |
20150203632 | METHOD FOR MAKING CARBON NANOTUBE COMPOSITE STRUCTURE - A method for making a carbon nanotube composite structure includes suspending a carbon nanotube layer in a reactor. A polymer monomer solution and an oxidant solution are gasified by a pressure to form polymer monomer solution gas and oxidant solution gas. The polymer monomer solution gas is polymerized and chemically bonded to the carbon nanotube layer in initiation of the oxidant solution gas. | 2015-07-23 |
20150203633 | COMPOSITION FOR OPTICAL MATERIALS, PROCESS FOR PRODUCTION THEREOF, AND OPTICAL MATERIALS MADE FROM THE COMPOSITION - The present invention has an object of providing, for example, a composition for optical materials which contains a polythiol that can be predicted and assessed, in a stage prior to polymerization/curing, as being clouded or not clouded after polymerization/curing, and thus can be determined as being good or defective. According to the present invention, the above-described object is achieved by, for example, a composition for optical materials which comprises a polythiol that exhibits an initial turbidity of 0.5 ppm or less and a turbidity of 0.6 ppm or less after the storage at 50° C. for 7 days, and an episulfide. Namely, an optical material made from a composition for optical materials which contains a polythiol satisfying the above turbidity requirements can be prevented from clouding to exhibit excellent transparency. | 2015-07-23 |
20150203634 | LINEAR CYCLODEXTRIN COPOLYMERS - Linear cyclodextrin copolymers and linear oxidized cyclodextrin copolymers containing an unoxidized and/or an oxidized cyclodextrin moiety integrated into the polymer backbone are described. Methods of preparing such copolymers are also described. The linear cyclodextrin copolymer and linear oxidized cyclodextrin copolymer of the invention may be used as a delivery vehicle of various therapeutic agents. | 2015-07-23 |
20150203635 | SILICONE RUBBER - Copolymers, as well as compounds, compositions, articles of manufacture, and methods of making thereof, are disclosed. The copolymers may generally exhibit flexibility properties and may generally have a high refractive index. The copolymers may generally be made by providing a dihydrodisiloxane and an aliphatic vinyl alcohol and combining the dihydrodisiloxane and the aliphatic vinyl alcohol under conditions that allow for hydrogenation of the aliphatic vinyl alcohol and result in coupling of the aliphatic vinyl alcohol to the dihydrodisiloxane to produce a hydroxyl substituted siloxane. | 2015-07-23 |
20150203636 | CYCLOALIPHATIC POLYPHOSPHITE POLYMER STABILIZERS - A polymeric polyphosphite and copolymeric polyphosphite is described which contains a cycloaliphatic moiety, preferably cyclohexane dimethanol, in the polyphosphite backbone chain. | 2015-07-23 |
20150203637 | METHOD FOR THE PREPARATION OF STABLE EMULSIONS OF POLYISOBUTENE - The invention relates to a method for preparing a stable and thin liquid polyisobutene emulsion comprising the steps of i) heating a polyisobutene polymer, optionally mixing said polyisobutene polymer with a wax and/or oil, thereby obtaining a pre-mix, ii) mixing said pre-mix in water containing one or more surfactants in a concentration of the surfactant of maximum 5% wt. at a controlled flow rate, which flow rate is sufficiently slow to form particles of the pre-mix, thereby obtaining a pre-emulsion, and iii) homogenising said pre-emulsion, thereby obtaining said polyisobutene emulsion with an average particle size of at maximum 100 μm. | 2015-07-23 |
20150203638 | NUCLEOPHILIC HIGH MOLECULAR WEIGHT POLYMER FUNCTIONALIZATION THROUGH ALKYLATION - A new and efficient method of functionalizing high molecular weight polymers through alkylation using a metal hetero alkylbase is described. This novel procedure can also be used to synthesize polymer-based macro-initiators containing radical initiating groups at the chain-ends for synthesis of block copolymers. | 2015-07-23 |
20150203639 | POLYTHIOPHENE STAR COPOLYMER CAPABLE OF BEING SELF-DOPED BY EXTERNAL STIMULUS, A METHOD FOR PRODUCING THE SAME, A CONDUCTIVE THIN FILM USING THE SAME, AND A METHOD FOR PRODUCING THE CONDUCTIVE THIN FILM - The present invention provides a method for producing polythiophene star copolymer capable of being self-doped by an external stimulus, which includes the steps of: forming a polythiophene macroinitiator made by introducing a living radical polymerizable functional group into an end of polythiophene or a derivative thereof; forming through living radical polymerization a polymer macroinitiator for providing by an external stimulus at least a dopant selected from the group consisting of sulfonic acid radical, carboxylic acid radical and phosphoric acid radical; and polymerizing the polythiophene macroinitiator added with the polymer macroinitiator and at least one kind of divinyl monomer to produce the polythiophene star copolymer. The polythiophene star copolymer capable of being self-doped by an external stimulus according to the present invention is a self-doped material to stably increase conductivity, and can be used as a material for a conductive film. | 2015-07-23 |
20150203640 | METHOD FOR PRODUCING CHLORINATED POLYVINYL CHLORIDE RESIN - The present invention relates to a method for producing chlorinated polyvinyl chloride resin in which polyvinyl chloride resin is chlorinated by radiating ultraviolet light in a reactor into which polyvinyl chloride resin and chlorine have been introduced, wherein the radiation of the ultraviolet light is performed by using at least one light source selected from the group consisting of an ultraviolet LED, an organic EL and an inorganic EL, the light source is disposed within the reactor, at least one radiation direction of the ultraviolet light is within a range of 30° or more and 115° or less with respect to a stirring direction of polyvinyl chloride resin, and an amount of ultraviolet light radiated within the range of 30° or more and 115° or less with respect to the stirring direction of polyvinyl chloride resin is 24% or more based on a total amount of ultraviolet light radiated from the light source taken as 100%. | 2015-07-23 |
20150203641 | PROCESS FOR PRODUCING HIGH MOLECULAR WEIGHT POLYETHYLENE - The invention relates to a process for producing an (ultra) high molecular weight polyethylene (HMWPE) article comprising:
| 2015-07-23 |
20150203642 | Random Mat and Fiber-Reinforced Composite Material Shaped Product - Provided is a fiber-reinforced composite material shaped product having isotropy and mechanical strength and a random mat used as an intermediate material thereof. | 2015-07-23 |
20150203643 | POLYETHYLENE COMPOUNDS HAVING NON-MIGRATORY SLIP PROPERTIES - A masterbatch having functionalized silicone with an epoxy group or a secondary amine group as a slip additive, the polyethylene compound that the silicone-containing masterbatch has been let down into, and the plastic articles and films from such compounds having improved slip properties are disclosed. The improved slip properties are evidenced by essentially no migration of the slip additive 12 weeks after manufacturing and a dynamic coefficient of friction value of less than 0.4 and a static coefficient of friction 0.5 or less as measured within the first day of manufacturing according to the ASTM D1894-01 method. | 2015-07-23 |
20150203644 | POLYMERIC SHEETS AND ARTICLES WRAPPED THEREWITH - A polymeric sheet having low density and comprising a low to non-existent amount of cyclic olefinic polymers (COP) and/or cyclic olefinic copolymers (COC). The overall density of the sheet may be lower than water. The sheet may be stretched and then heat shrinked onto an article. The sheet may be used as a label or package to wrap articles therewith. | 2015-07-23 |
20150203645 | LIGAND GRAFTED SUBSTRATES - Ligand-functionalized substrates are describe that are useful in selectively binding and removing biological materials from biological samples, and methods for preparing the same. | 2015-07-23 |
20150203646 | METHOD FOR PRODUCING LAMINATED POROUS SHEET COMPRISING POLYTETRAFLUOROETHYLENE AND CARBON PARTICLES - The method for producing the porous sheet of the present invention includes the steps of (I) preparing a plurality of sheet materials that contain polytetrafluoroethylene and carbon particles and (II) stacking the plurality of sheet materials over one another and rolling the stacked sheet materials. In the method for producing the porous sheet of the present invention, step (I) and step (II) may be repeated alternately. Further, as the sheet materials to be used in the production method of the present invention, a base sheet obtained by forming a mixture containing polytetrafluoroethylene and carbon particles into sheet form also can be used, or a laminated sheet obtained by stacking a plurality of base sheets over one another and rolling them also can be used, for example. | 2015-07-23 |
20150203647 | NANOCELLULAR THERMOPLASTIC FOAM AND PROCESS FOR MAKING THE SAME - Prepare a thermoplastic polymer foam having a porosity of 70% or more and at least one of: (i) an average cell size of 200 nanometers or less; and (ii) a nucleation density of at least 1×1015 effective nucleation sites per cubic centimeter of foamable polymer composition not including blowing agent using a foamable polymer composition containing a thermoplastic polymer selected from styrenic polymer and (meth)acrylic polymers, a blowing agent comprising at least 20 mole-percent carbon dioxide based on moles of blowing agent and an additive having a Total Hansen Solubility Parameter that differs from that of carbon dioxide by less than 2 and that is present at a concentration of 0.01 to 1.5 weight parts per hundred weight parts thermoplastic polymer. | 2015-07-23 |